About this trial
This is a multicenter, cross-sectional study. It is based on fecal methylation site detection, H. pylori susceptibility testing of fecal samples, and a combination of the two, compared with the "gold standard" imaging tests, CT, gastroscopy and/or pathology, for gastric cancer, benign diseases such as gastritis, and health check-ups.
Eligibility criteria
Qualifiers
Age ≥ 18 years old, male or female not limited.
Within 90 days, the gastroscopy and/or pathological results confirm the absence of gastric cancer.
Patients must be able to fully understand the informed consent form and be able to personally sign it.
Disqualifiers
Severe cardiac, hepatic, or renal insufficiency, or psychiatric disorders.
A previous history of malignant tumors of the upper gastrointestinal tract.
Women during pregnancy.
Those with undefined pathology.
Trial design
Treatments tested in this trial
- fecal methylation site-based testing and fecal Helicobacter pylori gastric cancer susceptibility gene-based testing